Review of Genetic Testing Companies During 2024

By Robert Michel | From the Volume XXXII, No. 1 – January 6, 2025 Issue

CEO SUMMARY: Investors in genetic testing companies are taking it on the chin these days. During 2024, a number of the nation’s largest firms providing genetic test services reported significant losses. Other genetic testing companies are dealing with class action lawsuits claiming that…

Read More

---

Invitae’s Troubled Journey: Rise, Fall, and Bankruptcy

By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue

ON MAY 7, THE REMNANTS OF GENETIC TESTING GIANT INVITAE (NYSE: NVTA) were scooped up by …

Read More

---

New CISA Draft Rule Mandates Rapid Reporting of Cyberattacks

By Robert Michel | From the Volume XXXI, No. 7 – May 20, 2024 Issue

CEO SUMMARY: There is another federal rule that will require compliance by clinical labs. An agency of U.S. Dept. of Homeland Security published a draft rule on April 4 that requires certain organizations—including hospitals, clinical labs, and pathology groups—to report, within 72 ho…

Read More

---

Change Healthcare Hit by Major Cyberattack

By Robert Michel | From the Volume XXXI, No. 4 – March 18, 2024 Issue

CEO SUMMARY: It was a classic ransomware attack against Change Healthcare, the business unit of Optum that is itself a division of UnitedHealth Group. On Feb. 21, this cyberattack shut down critical systems at Change Healthcare, such as those involved in accepting and forwarding prescript…

Read More

---

Genetic Testing Firm Invitae Files Chapter 11 Bankruptcy, Pursues Sale

By Robert Michel | From the Volume XXXI, No. 3 – February 26, 2024 Issue

INVITAE CORP., A MEDICAL GENETICS COMPANY, got the go ahead in mid-February from the U.S. Bankruptcy Court for the District of New Jersey “to find a buyer and exit from Chapter 11 by late July,” Reuters reported. Invitae said in a news release that it…

Read More

---

Lab News Briefs

By Robert Michel | From the Volume XXXI, Number 1 – January 16, 2024 Issue

Siemens to Explore Sale of Its IVD Diagnostics Unit Siemens Healthineers, Erlangen, Germany, is reportedly looking into options for sale of its in vitro diagnostics (IVD) segment. The company’s “review co…

Read More

---

Layoffs at Major Health Plans Slow Processing of Lab Claims

By Virchow | From the Volume XXXI, Number 1 – January 16, 2024 Issue

…

Read More

---

Lab News Briefs: Joint Commission, Bon Secours, Anthem, Walmart

By Scott Wallask | From the Volume XXX, No. 13 – September 11, 2023 Issue

Joint Commission Looks at Cyberattacks The Joint Commission issued a Sentinel Event Alert for hospitals to address cyberattacks. The alert pr…

Read More

---

With Z-codes, Will Other Payers Follow UnitedHealthcare’s Lead?

By Virchow | From the Volume XXX, No. 11 – July 31, 2023 Issue

EDITOR’S NOT…

Read More

---

Siemens Healthineers Plans to Streamline Product Offerings

By Scott Wallask | From the Volume XXX, No. 1 – January 3, 2023 Issue

DURING A 15-MONTH STRETCH FROM 2006-2007, Siemens Healthineers spent $14 billion to acquire three competing companies and their various technologies.  Today, Siemens is preparing to sunset as many as half of its legacy instruments and assays, whic…

Read More

---